Back to top

Analyst Blog

Zacks Equity Research

Encouraging News for Perrigo

MRK PRGO

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Perrigo Company’s (PRGO - Analyst Report) dominant position in the store brand over-the counter (OTC) drug market was further strengthened when it gained tentative approval from the US Food and Drug Administration (FDA) to market its store brand version of Merck & Co.'s (MRK - Analyst Report) Zegerid OTC. Perrigo intends to launch the drug immediately after its market formation.

We note that Zegerid OTC (omeprazole and sodium bicarbonate capsules 20mg/1100mg), which is approved for relieving frequent heartburn, recorded sales of approximately $42 million for the last 12 months. The  FDA tentative approval of Perrigo’s store brand version of Merck’s  Zegerid OTC comes close on the heels of the FDA approval of Perrigo’s abbreviated new drug applications (ANDAs) to market its OTC version of nicotine polacrilex mini lozenge, 2 mg (mint flavor) and 4 mg (mint flavor). Perrigo expects to start shipping the product by year end.

Perrigo’s broad line of store brand pharmaceutical products has the same active ingredients and comparable quality and efficacy as the national brands. This has helped the company become a dominant player in the store brand OTC drug market. Perrigo boasts of partnerships with retailers, pharmacies and mass merchandisers for whom it manages a wide range of activities including regulatory approvals, customized branding and packaging and in-store advertising.

Our Recommendation

We currently have a Neutral recommendation on Perrigo. The stock carries a Zacks #2 Rank (short-term Buy rating).

We believe Perrigo has a sustainable and diversified product portfolio. The company’s strong position in the brand OTC pharmaceutical market and growing generics and active pharmaceuticals ingredient (API) businesses are expected to drive growth in the coming quarters. We are also impressed by Perrigo’s strong pipeline.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%